Journal
GENES & DEVELOPMENT
Volume 32, Issue 17-18, Pages 1141-1154Publisher
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.316646.118
Keywords
breast cancer; cross-talk; cytokines; estrogen receptor; growth factors
Categories
Funding
- Novo Nordisk Foundation [NNF15OC0014136]
- Cancer Research UK
- ERC Consolidator Award
- Komen Scholarship
Ask authors/readers for more resources
Estrogen receptor a (ER) is the major driver of similar to 75% of breast cancers, and multiple ER targeting drugs are routinely used clinically to treat patients with ER+ breast cancer. However, many patients relapse on these targeted therapies and ultimately develop metastatic and incurable disease, and understanding the mechanisms leading to drug resistance is consequently of utmost importance. It is now clear that, in addition to estrogens, ER function is modulated by other steroid receptors and multiple signaling pathways (e.g., growth factor and cytokine signaling), and many of these pathways affect drug resistance and patient outcome. Here, we review the mechanisms through which these pathways impact ER function and drug resistance as well as discuss the clinical implications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available